Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

Alzheimer Disease Clinical Trial

Official title:

Phase 1 Randomized, Double-Blind, Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study of the Safety, Tolerability, and Pharmacokinetics of OLX-07010 in Healthy Adult and Elderly Participants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05696483
• Other study ID #: OLX-07010-01
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 20, 2023
• Est. completion date: March 1, 2025

Study information

• Verified date: July 2023
• Source: Oligomerix, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy elderly (51-75 of age inclusive). The effects of dosing with or without food in healthy adults will also be studied (optional).

Description:

This FIH Phase 1 randomized, double-blind, four-part study will be conducted to evaluate the safety, tolerability, and PK of the tau self-association inhibitor, OLX-07010 in single ascending doses, multiple ascending doses in healthy adult participants, and as a single dose in healthy elderly participants. There is an option for an additional part to evaluate the effects of food (fed and fasted) on OLX-07010 in healthy adult participants. This study will be divided into 4 parts: Part 1-Randomized Double-Blind Single Ascending Dose in Healthy Adult Participants; Part 2-Randomized Double-Blind Multiple Ascending Dose in Healthy Adults Participants; Part 3-Randomized Double-Blind Single Dose in Healthy Elderly Participants; and Part 4 (Optional)-Food Effect (Single Cohort, 2 Sequence, 2 Period Crossover Fed and Fasted) in Healthy Adult Participants.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 88
• Est. completion date: March 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Participant voluntarily agrees to participate and signs an approved informed consent prior to performing any of the Screening Visit procedures.

• Participant must be a healthy male or female of non-childbearing potential 18 to 50 years old inclusive, in Part 1, 2, and 4 of the study. Participant must be a healthy elderly male or female of non-childbearing potential 51-75 years old inclusive in Part 3 of the study.

• Male participants with body weight = 55 kg; and females with body weight = 50 kg and body mass index (BMI) between 18 and 30 kg/m2 (inclusive) for Part 1, 2, and 4 of the study; and BMI between 18 and 32 kg/m2 (inclusive) for Part 3 of the study.

• Female participants must be of non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or postmenopausal = 1 year with follicle -stimulating hormone [FSH] > 40 IU/L at screening).

Exclusion Criteria:

• Participant has clinically significant history or evidence of cardiovascular (CV), respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).

• Participant has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.

• Participant has a history of hypersensitivity to the study drug or any of the excipients or to medicinal products with similar chemical structures.

• Treatment with any investigational drug within the past 30 days prior to dosing.

• Use of any prescription drugs, herbal supplements, within 30 days prior to initial dosing, and over the counter (OTC) medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing. For elderly population in Part 3, allowed medications must be stable for at least 1 month.

• Clinically significant vital signs or ECG abnormality at screening and at baseline.

• Score of "yes" on specific items of the Suicidal Ideation section of the C-SSRS at the Screening Visit.

• History of any cancer within 5 years of screening (more than 10 years in remission).

• Any history of renal injury/kidney disease or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen (BUN) values in blood, or clinically relevant abnormal urinary constituents at Screening or Admission.

• Participant has any of the liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma glutamyl transferase [GGT]) or total bilirubin [TBL]) greater than the upper limit of normal (ULN), with the exception of isolated TBL elevation consistent with Gilbert's disease.

• Participants taking medications that are sensitive substrates for CYPC8, CYP2C19, CYP3A4, CYP1A2, and CYP2C9.

• Participant has a significant history of hypersensitivities or allergies to any medications, as determined by the PI/designee.

• Sexually active males not willing to use a condom during intercourse while taking the study drug and until EOS visit.

• Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant.

• Female participants are breastfeeding or female participants with a positive serum pregnancy test at the screening visit or positive urine pregnancy test at admission.

• Participants has poor venous access.

• Participant has history of alcohol and/or illicit drug abuse within 12 months prior dosing or positive alcohol/illicit drug test at screening and/or admission; smoking history (use of tobacco products in the previous 3 months prior dosing) or positive cotinine test at screening or admission.

• Participant has donated blood (> 500 mL) or blood products within 2 months prior to admission (Day -1). Plasma donation (> 200 mL) within 7 days prior to first dosing.

• Participant has previously been enrolled in this clinical study.

• Participant has a positive reverse transcription polymerase chain reaction (RT PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

• Participant has clinical signs and symptoms consistent with SARS-CoV-2 infection, e.g., fever, dry cough, dyspnea, sore throat, fatigue, or laboratory confirmed acute infection with SARS-CoV-2.

• Participant who had a severe course of COVID-19; (extracorporeal membrane oxygenation, mechanically ventilated, or Intensive Care Unit stay).

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• OLX-07010 Active
25 and 75 mg capsules
• OLX-07010 Placebo
25 and 75 mg capsules

Locations

Country	Name	City	State
United States	California Clinical Trials Medical Group, Inc	Glendale	California

Sponsors (1)

Lead Sponsor	Collaborator
Oligomerix, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events as Measured by NCI-CTCAE criteria	Safety and tolerability of OLX-07010 will be assessed by documenting adverse events occurring after single dose administration (Parts 1, 3 and 4) and multiple dose administration (Part 2)	After each dose of OLX-07010 through completion of dosing, up to 30 days
Primary	Incidence of Treatment-Emergent Adverse Events as Measured by Clinical Laboratory Measurements According to Established Clinical Normal Ranges	Blood and Urine samples will be taken after administration of OLX-07010 and values will be compared to baseline and established normal ranges to determine how OLX-07010 administration impacts normal body function	Change from baseline at 2-4 hours post-dose of OLX-07010
Primary	Incidence of Treatment-Emergent Adverse Events as Measured by ECG	ECGs will be used to measure changes to the heart after administration of OLX-07010	Change from baseline at 2, 4, and 8 hours and Days 2 and 4 post-dose of OLX-07010
Primary	Incidence of Treatment-Emergent Adverse Events as Measured by Neurological Examination	Neurological assessments will be performed to investigate the potential effect of the study drug on mental status, gait (normal/abnormal), coordination/incoordination, tremor, muscle tone, stereotypy and biceps reflexes	Change from baseline at Day 1, Day 4 (Parts 1 and 3) and Days 7 and 10 (Parts 2 and 4) post-dose of OLX-07010
Secondary	Maximum drug concentration in plasma (Cmax) of OLX-07010 after single ascending doses	The maximum drug concentration will be determined after a single ascending doses	Blood collection on Day 1, 2, 3, and 4. On Day 1 (pre-dose 0 hour, post-dose at 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, 7, 9, and 12 hours), Day 2 (24 hours post-dose), Day 3 (48 hours post-dose) and Day 4 (72 hours post-dose).
Secondary	Maximum drug concentration in plasma (Cmax) of OLX-07010 after multiple ascending doses	The maximum drug concentration will be determined after a single ascending doses	Day 1and Day 7 (pre-dose 0 hour, and post-dose at 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, 7, 9, 12 hours), Days 2 (24 hours post-dose) to Day 6 (pre-dose 0 hours), Day (24 hours post-dose), Day 9 (48 hours post-dose), and Day 10 (72 hours post-dose).
Secondary	Area under the concentration-time curve in plasma (AUC) of OLX-07010 after single ascending doses.	Determine the Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (tlast) and from pre-dose (time 0) extrapolated to infinite time (AUClast + Clast/?z) calculated using the linear-log trapezoidal rule.	Blood collection on Day 1, 2, 3, and 4. On Day 1 (pre dose 0 hour, post-dose at 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, 7, 9, and 12 hours), Day 2 (24 hours post-dose), Day 3 (48 hours post-dose) and Day 4 (72 hours post-dose).
Secondary	Area under the concentration-time curve in plasma (AUC) of OLX-07010 after multiple ascending doses.	Determine the Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (tlast) and from pre-dose (time 0) extrapolated to infinite time (AUClast + Clast/?z) calculated using the linear-log trapezoidal rule.	Day 1and Day 7 (pre-dose 0 hour, and post-dose at 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, 7, 9, 12 hours), Days 2 (24 hours post-dose) to Day 6 (pre-dose 0 hours), Day (24 hours post-dose), Day 9 (48 hours post-dose), and Day 10 (72 hours post-dose).
Secondary	Renal clearance and percent drug excreted in Urine after single and multiple ascending doses of OLX-07010.	Determine the the renal clearance and amount of OLX-07010 excreted in urine.	Part 1:Day 1 at 0 hour (pre-dose), 0-4; 4-8; 8-12; and 12-24 hours post-dose. Part 2: Day 1 and Day 7 at 0 hour (pre-dose), 0-4 hours; 4-8 hours; 8-12 hours; 12-24 hours.